Provectus Biopharma Company Profile (NYSE:PVCT)

About Provectus Biopharma

Provectus Biopharma logoProvectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: PVCT
  • CUSIP:
Key Metrics:
  • Previous Close: $0.13
  • 50 Day Moving Average: $0.2682
  • 200 Day Moving Average: $0.3593
  • 52-Week Range: $212,829,000.00 - $0.09
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.90
  • P/E Growth: 0.0000
  • Market Cap: $26.92M
  • Outstanding Shares: 212,829,000
Additional Links:
Companies Related to Provectus Biopharma:

Analyst Ratings

Consensus Ratings for Provectus Biopharma (NYSE:PVCT) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Provectus Biopharma (NYSE:PVCT)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Provectus Biopharma (NYSE:PVCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.04)ViewListenView Earnings Details
3/30/2016Q415($0.05)$1.08 millionViewListenView Earnings Details
11/5/2015Q315($0.03)$1.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Provectus Biopharma (NYSE:PVCT)
Current Year EPS Consensus Estimate: $-0.1200 EPS
Next Year EPS Consensus Estimate: $-0.1400 EPS

Dividends

Dividend History for Provectus Biopharma (NYSE:PVCT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Provectus Biopharma (NYSE:PVCT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Provectus Biopharma (NYSE:PVCT)
DateHeadline
seekingalpha.com logoProvectus prices equity offering; shares plummet 48% (NYSE:PVCT)
seekingalpha.com - August 25 at 7:08 PM
investors.com logoProvectus announces pricing of public offering to raise $6mln (NYSE:PVCT)
www.proactiveinvestors.com - August 25 at 7:08 PM
sg.finance.yahoo.com logoProvectus reports 2Q loss (NYSE:PVCT)
sg.finance.yahoo.com - August 10 at 10:05 AM
publicnow.com logoProvectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results (NYSE:PVCT)
www.publicnow.com - August 9 at 7:15 PM
seekingalpha.com logoProvectus Biopharmaceuticals reports Q2 results (NYSE:PVCT)
seekingalpha.com - August 9 at 5:19 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, … (NYSE:PVCT)
finance.yahoo.com - July 20 at 9:50 AM
seekingalpha.com logoProvectus Biopharma establishes Australian Subsidiary (NYSE:PVCT)
seekingalpha.com - July 14 at 10:37 AM
publicnow.com logoProvectus Biopharmaceuticals Will Present at 2016 BIO International Convention in San Francisco, CA (NYSE:PVCT)
www.publicnow.com - June 7 at 7:08 AM
publicnow.com logoProvectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page (NYSE:PVCT)
www.publicnow.com - June 1 at 8:03 AM

Social

Provectus Biopharma (NYSE:PVCT) Chart for Wednesday, August, 31, 2016


Last Updated on 8/31/2016 by MarketBeat.com Staff